At the Cell & Gene Therapy World Asia 2025 on September 10th, Dr. Wei-Kai Hua presented the latest progress of the autologous CAR-T therapy GF-CART01, currently in a Phase I clinical trial. Notably, the first patient achieved a Complete Metabolic Response (CMR) two months after CAR-T infusion, with imaging confirming complete tumor disappearance. This represents a significant milestone and a strong early signal of clinical potential. Additionally, Dr. Hua also addressed the key hurdles in developing CAR-T therapies for solid tumors—including limited tumor infiltration, heterogeneous antigen expression, and T cell exhaustion in the suppressive tumor microenvironment (TME). As a potential solution, GF-CART03 introduces a triple-CAR design with a modulator and an integrated safety switch. This unique approach is engineered for broad efficacy and safety across pan–solid tumor types, paving the way for future clinical needs. We’re excited by the progress and remain committed to advancing safer, more effective CAR-T therapies to patients worldwide.
